Premium
EFFECT OF 50 mg ENTERIC‐COATED ASPIRIN (ASTRIX) ON THROMBOXANE AND PROSTACYCLIN SYNTHESIS
Author(s) -
James MichaelJ.,
Walsh JohnA.,
Foreman RobertK.
Publication year - 1987
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1987.tb01257.x
Subject(s) - aspirin , prostacyclin , medicine , enteric coating , thromboxane , platelet , pharmacology , thromboxane b2 , gastroenterology , dosage form
Although low‐dose soluble aspirin can be recommended as a useful anti‐thrombotic drug regimen in patients with vascular disease, enteric‐coated preparations have a theoretical advantage for aspirin preparations which are to be ingested daily for many years. We have demonstrated that a 50 mg enteric‐coated aspirin formulation (astrix) which has an absorption rate much lower than soluble aspirin, is sufficient to inhibit platelet thromboxane synthesis while causing no major decrease in vascular prostacyclin synthesis.